No results for ‘’
Nectar Lifescience Ltd
₹11.44
(1.63%)
Sat, 20 Jun 2026, 03:09 pm
Health Technology
Pharmaceuticals: Major
24.5KNectar Lifescience EV/EBITDA Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 9.47 | 6.50 | 5.59 | 4.45 | 8.44 | 5.20 | 7.35 | 4.10 | 8.74 | 12.51 | 15.70 | 14.25 | 11.35 | 8.06 | 6.98 | 0 | 21.53 | 0 | 135.20 | 0 |
| Price to book ratio | 1.99 | 0.97 | 1.08 | 0.57 | 1.31 | 0.74 | 0.69 | 0.40 | 0.59 | 0.86 | 0.89 | 0.78 | 0 | 0.35 | 0.20 | 0.39 | 0.50 | 0.33 | 0.63 | 0.54 |
| Price to sales ratio | 1.39 | 0.68 | 0.57 | 0.32 | 0.93 | 0.51 | 0.41 | 0.22 | 0.33 | 0.50 | 0.51 | 0.48 | 0.32 | 0.14 | 0.09 | 0.27 | 0.32 | 0.23 | 0.40 | 0.31 |
| Price to cash flow ratio | 0 | 45.65 | 2.78 | 2.25 | 0 | 0 | 7.20 | 1.34 | 4.22 | 21.39 | 16.66 | 8.96 | 0 | 3.95 | 1.37 | 0 | 29.83 | 6.36 | 4.50 | 5.35 |
| Enterprise value | 498Cr | 681Cr | 877Cr | 905Cr | 1351Cr | 1299Cr | 1556Cr | 1224Cr | 1391Cr | 1718Cr | 1777Cr | 1654Cr | 1538Cr | 1265Cr | 979Cr | 1295Cr | 1381Cr | 1092Cr | 1290Cr | 1078Cr |
| Enterprise value to EBITDA ratio | 8.18 | 8.42 | 6.92 | 6.40 | 6.88 | 5.80 | 6.79 | 4.22 | 4.83 | 6.46 | 7.40 | 7.32 | 6.46 | 4.74 | 4.41 | 11.62 | 8.67 | 19.84 | 8.35 | 0 |
| Debt to equity ratio | 0.84 | 1.91 | 1.71 | 2.32 | 0.97 | 1.10 | 1.33 | 1.01 | 0.93 | 0.97 | 1.01 | 0.87 | 0.90 | 0.82 | 0.69 | 0.85 | 0.79 | 0.71 | 0.59 | 0.61 |
| Return on equity % | 28.26 | 21.69 | 29.61 | 18.04 | 19.98 | 15.37 | 9.73 | 10.38 | 6.92 | 7.03 | 5.67 | 5.64 | 5.06 | 4.40 | 2.84 | -6.67 | 2.33 | -2.25 | 0.47 | -11.23 |
Nectar Lifescience Ltd Enterprise Value to EBITDA Ratio
The Nectar Lifescience Ltd Enterprise Value to EBITDA Ratio is a key financial metric used by investors to evaluate Nectar Lifescience Ltd's valuation, profitability, and overall financial performance. Tracking the Nectar Lifescience Ltd Enterprise Value to EBITDA Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Nectar Lifescience Ltd (NSE: NECLIFE, BSE: 532649) is currently trading at ₹11.44, with a market capitalization of ₹223.4Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Nectar Lifescience Ltd Enterprise Value to EBITDA Ratio is essential for fundamental analysis.
Nectar Lifescience Ltd Enterprise Value to EBITDA Ratio Current Value
The current Nectar Lifescience Ltd Enterprise Value to EBITDA Ratio stands at 0.
The Nectar Lifescience Ltd Enterprise Value to EBITDA Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Nectar Lifescience Ltd Enterprise Value to EBITDA Ratio Historical Trend
The Nectar Lifescience Ltd Enterprise Value to EBITDA Ratio has shown the following historical trend:
- 2024: 0
- 2023: 8.35
- 2022: 19.84
- 2021: 8.67
- 2020: 11.62
The decline in Nectar Lifescience Ltd Enterprise Value to EBITDA Ratio indicates improving financial efficiency or better earnings growth.
What Nectar Lifescience Ltd Enterprise Value to EBITDA Ratio Indicates for Investors
The Nectar Lifescience Ltd Enterprise Value to EBITDA Ratio plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Nectar Lifescience Ltd.
Nectar Lifescience Ltd Enterprise Value to EBITDA Ratio Analysis Summary
The Nectar Lifescience Ltd Enterprise Value to EBITDA Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Nectar Lifescience Ltd Enterprise Value to EBITDA Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Nectar Lifescience Ltd Enterprise Value to EBITDA Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.